CompanyANRONYSEMountain View, CA

Alto Neuroscience

Alto Neuroscience develops small-molecule therapeutics for psychiatric disorders including treatment-resistant depression, major depressive disorder, bipolar depression, and schizophrenia.

Stories only

SEC EDGAR ClinicalTrials.gov altoneuroscience.com

8-KAug 27Latest SEC filing, period to Aug 26

Aug 27Latest story

August 2026

Alto Neuroscience elevates CFO Nicholas Smith to president role

Aug 27PeopleAlto Neuroscience

Alto Neuroscience adds third Phase 3 trial for ALTO-207, cites Nature Medicine data

Aug 12Quarterly updateAlto Neuroscience

July 2026

Alto Neuroscience prices $93.9 million stock offering to fund ALTO-207 trial

Jul 14PartnershipAlto Neuroscience

Alto Neuroscience prices $100 million offering, plans Phase 3 trial of ALTO-207

Jul 14FinancingAlto Neuroscience

Alto Neuroscience plans added Phase 3 trial for depression drug ALTO-207

Jul 13Quarterly updateAlto Neuroscience